TCL Archive Concurrent Trastuzumab and Anthracyclines Not Necessary for High Pathological Response November 29, 2013
TCL Archive A letter about FDA oncology consolidation reopens debate among cancer groups; FDA asks groups not to send letters, invites discussion. June 4, 2004
TCL Archive ODAC Says Clear Clinical Benefit Required When Sponsors Claim Progression Delay July 17, 2009
